eosine yellowish-(ys) has been researched along with celastrol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, K; Wang, J; Xiang, G | 1 |
| Hou, G; Jing, M; Li, J; Liu, J; Sun, H; Sun, M; Wang, C; Wang, Q; Xin, W; Yang, J; Zhang, L | 1 |
2 other study(ies) available for eosine yellowish-(ys) and celastrol
| Article | Year |
|---|---|
Celastrol alleviates murine lupus nephritis via inducting CD4+Foxp3+ regulatory T cells.
Topics: Animals; Creatinine; Cytokines; Eosine Yellowish-(YS); Forkhead Transcription Factors; Hematoxylin; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Pentacyclic Triterpenes; T-Lymphocytes, Regulatory | 2022 |
Celastrol inhibits rheumatoid arthritis by inducing autophagy via inhibition of the PI3K/AKT/mTOR signaling pathway.
Topics: Animals; Arthritis, Rheumatoid; Autophagy; Beclin-1; Cell Proliferation; Collagen Type II; Cytokines; Deoxyuridine; Eosine Yellowish-(YS); Hematoxylin; Mice; Pentacyclic Triterpenes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinones; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Necrosis Factor-alpha | 2022 |